KANEKA
19.1.2023 04:57:38 CET | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: Liège, Belgium; President: Lieven Janssens), a wholly owned group company in Europe. We plan to start operation sequentially from the end of 2023 with a capital investment of 2 billion JPY and a production capacity that is around 5 times higher than the current capacity. Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118006042/en/
Kaneka Eurogentec S.A. building (Photo: Business Wire)
mRNA, which has been rapidly implemented in vaccines against COVID-19, is expected to be applied not only to vaccines for other infectious diseases but also to therapeutics for genetic diseases, cancer and so on. The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years. They provide plasmid DNA, recombinant proteins, oligonucleotide*6 and so on as drug substances for pharmaceutical companies worldwide. In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Regarding the priority area of Health Care, Kaneka will continue to provide solutions globally for health issues through the growth of its biopharmaceutical business.
*1. |
GMP (Good Manufacturing Practice): A system for ensuring that products are consistently produced and controlled according to quality standards. |
*2. |
mRNA: An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics. |
*3. |
CDMO: Contract Development and Manufacturing Organization. |
*4. |
Food and Drug Administration (FDA): US governmental agency dealing with approval and supervision of violation of products which may be used by consumers in their daily life such as pharmaceutical products, cosmetics, medical devices, veterinary drugs and toys. |
*5. |
plasmid DNA: A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division. |
|
It is conventionally used in processes for producing biopharmaceuticals such as therapeutic proteins and has been applied to genetic medicines and vaccines in recent years. |
*6. |
Oligonucleotide: Short polymeric sequences of nucleotides (RNA or DNA). It is used as drug substance of nucleic acid therapeutics. |
[General description of Kaneka Eurogentec S.A.]
Headquarters: Liège, Belgium
President: Lieven Janssens
Description of business: Manufacturing and sales of proteins, nucleic acids and peptides for medicinal, diagnostic and basic research uses
Established: 1985
Capital: 31 million euros
URL: http://www.eurogentec.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches Android 16 Smart Modules for 4G and 5G IoT Devices18.8.2026 10:00:00 CEST | Press release
New SH602FA and SE505FE smart modules combine Android 16 with integrated wireless connectivity to accelerate industrial and commercial IoT development Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of two new Android 16 smart modules: the SH602FA, a high-performance 4G smart module, and the SE505FE, an entry-level 5G smart module. Designed for industrial and commercial IoT applications, the new modules combine Android 16, integrated wireless connectivity and powerful multimedia capabilities in compact form factors that simplify development and accelerate time-to-market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818272981/en/ Quectel launches Android 16 smart modules for 4G and 5G IoT devices By bringing Android 16 to both 4G and 5G IoT devices, Quectel enables developers to build smarter connected products with richer user interfaces, enhanced multimedia performance
Queue-it Announces Majority Investment from THL Partners18.8.2026 09:00:00 CEST | Press release
Partnership will support continued product innovation and global expansion for the online traffic orchestration platform Queue-it, a global provider of online traffic orchestration solutions, today announced that it has entered a definitive agreement for a majority investment from THL Partners (“THL”), a premier investment firm investing in middle-market growth companies. Together, THL and Queue-it will focus on accelerating product innovation and expanding the company’s global reach. Founded and headquartered in Denmark, Queue-it helps enterprises and public organizations manage online traffic surges, protect digital infrastructure, mitigate bots and abuse, and deliver fair, reliable access to critical online services. Its platform is trusted by organizations around the world and operates across ticketing, retail, government, financial services, and other mission-critical industries. THL’s partnership with Queue-it builds on the firm’s longstanding investment focus on IT Operations &
THL Partners opkøber danske Queue-it af GRO og investerer i næste fase af den spændende vækstrejse18.8.2026 09:00:00 CEST | Pressemeddelelse
Partnerskabet skal understøtte fortsat produktinnovation og global ekspansion for teknologiplatformen til orkestrering af onlinetrafik. Queue-it, global leverandør af løsninger til orkestrering af onlinetrafik, annoncerede i dag, at virksomheden har indgået en endelig aftale om en majoritetsinvestering fra THL Partners ("THL"), et førende investeringsselskab med fokus på mellemstore vækstvirksomheder. Sammen vil THL og Queue-it fokusere på at accelerere produktinnovation og udvide virksomhedens globale rækkevidde. Queue-it blev grundlagt i Danmark i 2010 og har hovedkontor i København men servicerer i dag de største brands og organisationer i hele verden. Virksomheden hjælper virksomheder og offentlige organisationer med at håndtere spidsbelastninger i onlinetrafik, beskytte digital infrastruktur, reducere bot-aktivitet og misbrug samt sikre fair og pålidelig adgang til kritiske digitale tjenester. Platformen anvendes af organisationer over hele verden inden for blandt andet billetsalg
Beno Opens Luxury Waterfront Guest Lounge at Marsa Al Arab in Partnership with Jumeirah Group18.8.2026 09:00:00 CEST | Press release
Beno, Dubai's luxury experiences platform, announced the opening of a new premium guest lounge at Marsa Al Arab, developed in partnership with Jumeirah Group, the hospitality arm of Dubai Holding. The lounge adds a permanently staffed guest-services layer to one of Dubai's newest ultra-luxury marine developments. Marsa Al Arab Marina, operated by D-Marin adjacent to Jumeirah Burj Al Arab, offers 82 berths for yachts of up to 61 metres and holds Superyacht Ready and Blue Flag certifications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818185241/en/ Beno's guest lounge on the marina promenade at Marsa Al Arab, Dubai, with the 115-ft yacht Santorini berthed opposite (Photo: AETOSWire) Beno coordinates yacht charters from the lounge, supported by a nine-vessel fleet berthed at the marina. Among them is Santorini, a 115-ft superyacht featuring five cabins that can accommodate up to 12 overnight guests and up to 80 guests fo
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 21:44:00 CEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom